Memigmin

Memantine hydrochloride, the active ingredient in Memigmin, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer's disease in adults. GNH USA supplies Memigmin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memigmin is a NMDA receptor antagonist used in the management of dementia-related conditions. - Moderate to severe Alzheimer's disease: improves cognition and functional abilities in patients. - Behavioral symptoms in Alzheimer's disease: may reduce agitation and aggression. - Functional decline in Alzheimer's disease: helps maintain daily living activities.

Memigmin may cause a range of adverse reactions.

Common Side Effects: - Dizziness: transient light‑headedness or loss of balance. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Hypertension: elevated blood pressure readings. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: hallucinations or delusional thoughts.

Before initiating Memigmin, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for seizure activity. - Cardiovascular disease: use with caution in patients with hypertension or arrhythmias. - Concomitant NMDA antagonists: avoid duplication to reduce neurotoxicity risk. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Memigmin can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Other NMDA antagonists: combined use can heighten neuropsychiatric effects. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive effects. - Diuretics: can affect electrolyte balance and renal clearance. - Anticholinergic agents: may worsen cognitive side effects.